IP Verse

Vaccine For Pcv2 And Mycoplasma - EP2994162

The patent EP2994162 was granted to Pharmgate Biologics on Apr 7, 2021. The application was originally filed on May 8, 2014 under application number EP14794866A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2994162

PHARMGATE BIOLOGICS
Application Number
EP14794866A
Filing Date
May 8, 2014
Status
Granted And Under Opposition
Mar 5, 2021
Publication Date
Apr 7, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOEHRINGER INGELHEIM VETMEDICAJan 7, 2022HOFFMANN EITLEADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8008001
DESCRIPTIONUS8119143
INTERNATIONAL-SEARCH-REPORTUS2003092897
INTERNATIONAL-SEARCH-REPORTUS2009092636
INTERNATIONAL-SEARCH-REPORTUS2009317423
INTERNATIONAL-SEARCH-REPORTUS2010062018
INTERNATIONAL-SEARCH-REPORTUS2011129494
OPPOSITIONEP0571648
OPPOSITIONUS2003092897
OPPOSITIONUS2004223982
OPPOSITIONUS2009317423
OPPOSITIONUS2011129494
OPPOSITIONWO2010044889
OPPOSITIONWO2011031850
OPPOSITIONWO2013152083
OPPOSITIONWO2013152086
OPPOSITIONWO2014182872
SEARCHUS5733555
SEARCHWO03005952
SEARCHWO9517210

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- "Disease surveillance at slaughter", POINTON et al., Diseases of Swine, Iowa State University Press, (19990000), pages 1111 - 1132
DESCRIPTION- HITCHMAN et al., "Baculovirus Expression Systems for Recombinant Protein Production in Insect Cells", Rec. Pat. Biotechnol., (20090000), vol. 3, pages 46 - 54, XP002630666
DESCRIPTION- SUN et al., Vaccine, (20090000), vol. 27, pages 1787 - 1796
OPPOSITION- Anonymous, "Product information ® Circoflex - MzcoFLEX™", Boehringer Ingelheim, (20080623), pages 1 - 10, XP055898825
OPPOSITION- Anonymous, "Safety data sheet CircoFLEX", Boehringer Ingelheim, pages 1 - 6, XP055898848
OPPOSITION- Anonymous, "Safety Data sheet MycoFLEX®", Boehringer Ingelheim, pages 1 - 7, XP055898840
OPPOSITION- Anonymous, "Setting higher standards in pork production Benchmark - spring edition", Pigchamp, (20120000), pages 18 - 19, XP055898912
OPPOSITION- BLOOD et al., "Performance of weaned pigs vaccinated with 3FLEX? compared to pigs vaccinated with Ingelvac® CircoFLEX-MycoFLEX?and Ingelvac® PRRS MLV in separate injections", Swine Conference, (20110000), pages 1 - 2, XP055898872
OPPOSITION- EGGEN et al., "One-dose vaccination against Mycoplasma hyopneumoniae and Porcine Circovirus Type 2", IPVS, (20100000), page 110, XP002740787
OPPOSITION- EICHMEYER et al., "Efficacy evaluation of a mixed Mycoplasma hyopneumoniae bacterin and a porcine circovirus type 2 vaccine", American Association of Swine Vet., (20090000), pages 299 - 300, XP055898883
OPPOSITION- FARRERE S et al., "Serology and safety of the simultaneous use of Porcilis® PCV and M+PAC® in the field", IPVS, (20100000), page 408, XP055898713
OPPOSITION- Haiwick G; Eichmeyer M; Roof And E Robb M, "Trivalent vaccine mixture protects against simultaneous challenge with M. hyopneumoniae, PCV2, and PRRS virus", Swine Conference, (20100000), page 176, XP055565903
OPPOSITION- Juan Palacios, "Economic evaluation of a combined vaccination against PCV-2 and Mh on a commercial farm", IPVS, (20100000), page 1, XP055259194
OPPOSITION- KIM et al., "Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2", Vaccine, (20110000), vol. 29, pages 3206 - 3212, XP055898828
OPPOSITION- PAYNE et al., "The effect of commercial combination PCV2/Mycoplasma hyopneumoniae vaccination products on wean to finish performance", Swine Conference, (20120000), vol. 39, pages 1 - 2, XP055898802
OPPOSITION- WILLIAM E. PAUL, "Chapter 43", Fundamental immunology seventh edition, pages 1042 - 1046, XP055898737
OPPOSITION- VANDEPAPELIERE et al., "Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults", Vaccine, (20050000), vol. 23, doi:10.1016/j.vaccine.2004.11.034, pages 2591 - 2601, XP004789514
OPPOSITION- XIAO et al., "Improvement of a commercial foot-and-mouth disease vaccine by supplement of Quil A", Vaccine, (20070000), vol. 25, doi:10.1016/j.vaccine.2007.04.027, pages 4795 - 4800, XP022098623
OPPOSITION- SONG et al., "Ginseng stem-leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice", Vaccine, (20090000), vol. 27, doi:10.1016/j.vaccine.2008.10.030, pages 51 - 55, XP025714108
OPPOSITION- SUN et al., "Advances in saponin-based adjuvants", Vaccine, (20090000), vol. 27, doi:10.1016/j.vaccine.2009.01.091, pages 1787 - 1796, XP026002489
SEARCH- Alex Eggen ET AL, "Combining Mycoplasma hyopneumoniae and Porcine Circovirus Type 2, a research report", Proceedings of the 5th Asian Pig Veterinary Society Congress7-9 March 2011, Pattaya, Thailand, (20110101), URL: http://www.vet.chula.ac.th/vet2014/Ebook/ebook/APVS2011/context/papers/poster/P109.pdf, (20161103), XP055258982 [Y] 1-23 * The whole document but see e.g. the right column, last paragraph *
SEARCH- Alvaro Ruiz ET AL, "Porcine Circovirus Associated Diseases (PCVAD) - Control - Clinical and pathologic lesions after simultaneous vaccination with PCV2 and Mycoplasma vaccine in 3 week old piglets", Proceedings of the 21st IPVS Congress, Vancouver, Canada - July 18-21, 2010, no. Poster P.132, (20100721), URL: http://orbit.dtu.dk/fedora/objects/orbit:63423/datastreams/file_5574380/content, (20160317), XP055259199 [Y] 1-23 * the whole document *
SEARCH- EGGEN A A ET AL, "One-dose vaccination against Mycoplasma hyopneumoniae and porcine circovirus type 2", PROCEEDINGS OF THE 21ST INTERNATIONAL PIG VETERINARY SOCIETY (IPVS) CONGRESS 2010 ; 19-21 JULY, 2010; VANCOUVER, CANADA,, (20100719), page 110, XP002740787 [Y] 1-23 * The whole document but see e.g. the right column, last paragraph *
SEARCH- FARRERES J ET AL, "Serology and safety of the simultaneous use of Porcilis PCV and M+PAC in the field", PROCEEDINGS OF THE 21ST IPVS CONGRESS, VANCOUVER, CANADA - JULY 18-21, 2010. 1036. POSTER PRESENTATIONS,, (20100718), page 408, XP002740786 [Y] 1-23 * The whole document *
SEARCH- HERBICH E ET AL, "[Field trial on the simultaneous vaccination against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae].", (20130501), Tierarztl Prax Ausg G Grosstiere Nutztiere, URL: https://www.ncbi.nlm.nih.gov/pubmed/24126996, (20161103), XP002763787 [Y] 1-23 * The whole document but see in particular the last paragraph *
SEARCH- SUN H X ET AL, "Advances in saponin-based adjuvants", VACCINE, ELSEVIER LTD, GB, vol. 27, no. 12, doi:10.1016/J.VACCINE.2009.01.091, ISSN 0264-410X, (20090313), pages 1787 - 1796, (20090207), XP026002489 [Y] 1-23 * See e.g. the abstract *
SEARCH- RIVERA E ET AL, "Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants", VACCINE, ELSEVIER LTD, GB, (20030307), vol. 21, no. 11-12, doi:10.1016/S0264-410X(02)00518-2, ISSN 0264-410X, pages 1149 - 1157, XP004404291 [Y] 1-23 * See e.g. the title, abstract, or the right colimn on page 1149 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents